Literature DB >> 31814222

Screening and management of preinvasive lesions of the cervix: Good clinical practice recommendations from the Federation of Obstetrics and Gynaecologic Societies of India (FOGSI).

Neerja Bhatla1, Seema Singhal1, Usha Saraiya2, Shikha Srivastava3, Sarita Bhalerao4, Saritha Shamsunder5, Niranjan Chavan6, Partha Basu7, C N Purandare8.   

Abstract

In India, there are marked variations in resources for cervical cancer screening. For the first time, resource-stratified screening guidelines have been developed that will be suitable for low middle-income countries with similar diversities. The current article describes the process and outcomes of these resource stratified guidelines for screening and treatment of preinvasive lesions of cervix. Evidence from literature was collated and various guidelines were reviewed by an expert panel. Based on the level of evidence, guidelines were developed for screening by human papillomavirus (HPV) testing, cytology and visual inspection after application of acetic acid (VIA), and management of screen positive lesions in different resource settings. Expert opinion was used for certain country-specific situations. The healthcare system was stratified into two resource settings - good or limited. The mode of screening and treatment for each was described. HPV testing is the preferred method for cervical cancer screening. VIA by trained providers is especially suitable for low resource settings until an affordable HPV test becomes available. Healthcare providers can choose the most appropriate screening and treatment modality. A single visit approach is encouraged and treatment may be offered based on colposcopy diagnosis ('see and treat') or even on the basis of HPV test or VIA results ('screen and treat'), if compliance cannot be ensured. The Federation of Obsterician and Gynaecologists of India Good Clinical Practice Recommendations (FOGSI) GCPR are appropriately designed for countries with varied resource situations to ensure an acceptable cervical cancer prevention strategy.
© 2019 Japan Society of Obstetrics and Gynecology.

Entities:  

Keywords:  cervical cancer screening; good clinical practice; prevention; recommendations; resource-based; single visit approach

Year:  2019        PMID: 31814222     DOI: 10.1111/jog.14168

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  5 in total

1.  Cervical Cancer Screening in HIV-Positive Women in India: Why, When and How?

Authors:  Amulya Boddu; Neerja Bhatla; Shachi Vashist; Sandeep Mathur; Reeta Mahey; Jayashree Natarajan; Ria Malik; Perumal Vanamail; Shweta Rai; Aruna Kumari; Lalit Dar; Naveet Wig
Journal:  J Obstet Gynaecol India       Date:  2021-02-19

2.  Experience of Human Papillomavirus Vaccination Project in a Community Set Up-An Indian Study.

Authors:  Ranajit Mandal; Dipanwita Banerjee; Krishnendu Gupta; Puja Chatterjee; Manisha Vernekar; Chandrima Ray
Journal:  Asian Pac J Cancer Prev       Date:  2021-03-01

Review 3.  Screening for cervical cancer: Choices & dilemmas.

Authors:  Shalini Rajaram; Bindiya Gupta
Journal:  Indian J Med Res       Date:  2021-08       Impact factor: 5.274

Review 4.  Recommendations for the prevention, screening, diagnosis, staging, and management of cervical cancer in areas with limited resources: Report from the International Gynecological Cancer Society consensus meeting.

Authors:  Fernando Cotait Maluf; Graziela Zibetti Dal Molin; Andreia Cristina de Melo; Eduardo Paulino; Douglas Racy; Robson Ferrigno; Pedro Luiz Serrano Uson Junior; Reitan Ribeiro; Renato Moretti; Jose Carlos Sadalla; Angelica Nogueira-Rodrigues; Filomena Marino Carvalho; Glauco Baiocchi; Donato Callegaro-Filho; Nadeem R Abu-Rustum
Journal:  Front Oncol       Date:  2022-08-18       Impact factor: 5.738

Review 5.  Cervical Cancer Prevention Efforts in India.

Authors:  Neerja Bhatla; Jyoti Meena; Sarita Kumari; Dipanwita Banerjee; Prerana Singh; Jayashree Natarajan
Journal:  Indian J Gynecol Oncol       Date:  2021-06-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.